New CEO Forster eyes capital raise for F-star

Immuno-oncology company F-star Biotechnology Ltd. (Cambridge, U.K.) named Eliot Forster as CEO, replacing John Haurum. Forster was CEO of Oxford-based TCR biologics play Immunocore Ltd. (Abingdon, U.K.), which he left in February.

Since becoming CEO in 2012, Haurum helped build out F-star's Modular Antibody Technology, a bispecific mAb platform, and created an asset-centric structure in which new programs are housed in F-star subsidiaries and could therefore receive targeted financing from investors or be out-licensed or acquired by industry partners. F-star has completed four licensing deals under the asset-centric model. In total, the company has raised about $250 million from both deals and venture financing...